Four-Drug Combo for HCV Shows Early Promise

(MedPage Today) — Combining traditional therapy for HCV infection with the newly approved drug telaprevir (Incivek) and an investigational oral HCV polymerase inhibitor boosted 24-week complete virologic response rates to 90% in a phase II study, the drugs’ manufacturer said.

Post a Comment

Comments are closed.